 |
PDBsum entry 1bda
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Hydrolase/hydrolase inhibitor
|
PDB id
|
|
|
|
1bda
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.4.21.68
- t-plasminogen activator.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Specific cleavage of Arg-|-Val bond in plasminogen to form plasmin.
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
EMBO J
16:4797-4805
(1997)
|
|
PubMed id:
|
|
|
|
|
| |
|
Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA.
|
|
M.Renatus,
R.A.Engh,
M.T.Stubbs,
R.Huber,
S.Fischer,
U.Kohnert,
W.Bode.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Tissue type plasminogen activator (tPA) is the physiological initiator of
fibrinolysis, activating plasminogen via highly specific proteolysis; plasmin
then degrades fibrin with relatively broad specificity. Unlike other
chymotrypsin family serine proteinases, tPA is proteolytically active in a
single-chain form. This form is also preferred for therapeutic administration of
tPA in cases of acute myocardial infarction. The proteolytic cleavage which
activates most other chymotrypsin family serine proteinases increases the
catalytic efficiency of tPA only 5- to 10-fold. The X-ray crystal structure of
the catalytic domain of recombinant human single-chain tPA shows that Lys156
forms a salt bridge with Asp194, promoting an active conformation in the
single-chain form. Comparisons with the structures of other serine proteinases
that also possess Lys156, such as trypsin, factor Xa and human urokinase
plasminogen activator (uPA), identify a set of secondary interactions which are
required for Lys156 to fulfil this activating role. These findings help explain
the anomalous single-chain activity of tPA and may suggest strategies for design
of new therapeutic plasminogen activators.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Figure 1 Stereo ribbon plot of the catalytic domain of sc-tPA in
'standard' orientation. The inhibitor
(dansyl-Glu-Gly-Arg-chloromethylketone) shown by green sticks is
covalently bonded to Ser195 and His57 of the catalytic triad.
Key sc-tPA residues are shown as yellow sticks: Asp102, His57
and Ser195 of the catalytic triad; Asp189 at the base of the S1
specificity pocket; and Asp194 and Lys156 which form a salt
bridge in the activation pocket. The red ribbon shows the
conformation of the N-terminal activation loop which includes
the plasmin cleavage site. Some loops arranged around the active
site are labelled: the mainly disordered 37 loop and the 110
loop to the east; the partially disordered 186 loop to the
south-west is in proximity to the activation loop. The figure
was made with SETOR (Evans, 1993).
|
 |
Figure 2.
Figure 2 Stereo plot of the activation domain environment of
sc-tPA involving residues of the activation pocket, the
activation loop and Lys156. Lys156 (blue) stabilizes the active
conformation of sc-tPA via formation of a salt bridge with
Asp194 (red). The strength of this interaction is presumably
increased by the concerted solvent shielding effect of the (red)
activation loop and of the hydrophobic residues Ile16, Phe21 and
His144 (yellow). Lysines 17 and 143, which were considered
potential activators of sc-tPA (Wallén et al., 1983; Petersen et
al., 1990) are also shown (blue). Residues His188, Arg186A and
Asn186F of the 186 loop (yellow) are presumed to be responsible
for the conformational stabilization of this loop.
|
 |
|
|
|
| |
The above figures are
reprinted
from an Open Access publication published by Macmillan Publishers Ltd:
EMBO J
(1997,
16,
4797-4805)
copyright 1997.
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
C.S.Craik,
M.J.Page,
and
E.L.Madison
(2011).
Proteases as therapeutics.
|
| |
Biochem J,
435,
1.
|
 |
|
|
|
|
 |
J.Schaller,
and
S.S.Gerber
(2011).
The plasmin-antiplasmin system: structural and functional aspects.
|
| |
Cell Mol Life Sci,
68,
785-801.
|
 |
|
|
|
|
 |
D.Belorgey,
P.Hägglöf,
M.Onda,
and
D.A.Lomas
(2010).
pH-dependent stability of neuroserpin is mediated by histidines 119 and 138; implications for the control of beta-sheet A and polymerization.
|
| |
Protein Sci,
19,
220-228.
|
 |
|
|
|
|
 |
A.A.Komissarov,
A.P.Mazar,
K.Koenig,
A.K.Kurdowska,
and
S.Idell
(2009).
Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits.
|
| |
Am J Physiol Lung Cell Mol Physiol,
297,
L568-L577.
|
 |
|
|
|
|
 |
E.Di Cera
(2009).
Serine proteases.
|
| |
IUBMB Life,
61,
510-515.
|
 |
|
|
|
|
 |
J.A.Huntington
(2009).
Slow thrombin is zymogen-like.
|
| |
J Thromb Haemost,
7,
159-164.
|
 |
|
|
|
|
 |
M.Onda,
D.Belorgey,
L.K.Sharp,
and
D.A.Lomas
(2005).
Latent S49P neuroserpin forms polymers in the dementia familial encephalopathy with neuroserpin inclusion bodies.
|
| |
J Biol Chem,
280,
13735-13741.
|
 |
|
|
|
|
 |
M.T.Murakami,
and
R.K.Arni
(2005).
Thrombomodulin-independent activation of protein C and specificity of hemostatically active snake venom serine proteinases: crystal structures of native and inhibited Agkistrodon contortrix contortrix protein C activator.
|
| |
J Biol Chem,
280,
39309-39315.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
P.Gál,
V.Harmat,
A.Kocsis,
T.Bián,
L.Barna,
G.Ambrus,
B.Végh,
J.Balczer,
R.B.Sim,
G.Náray-Szabó,
and
P.Závodszky
(2005).
A true autoactivating enzyme. Structural insight into mannose-binding lectin-associated serine protease-2 activations.
|
| |
J Biol Chem,
280,
33435-33444.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
W.Bode
(2005).
The structure of thrombin, a chameleon-like proteinase.
|
| |
J Thromb Haemost,
3,
2379-2388.
|
 |
|
|
|
|
 |
C.A.Ibarra,
G.E.Blouse,
T.D.Christian,
and
J.D.Shore
(2004).
The contribution of the exosite residues of plasminogen activator inhibitor-1 to proteinase inhibition.
|
| |
J Biol Chem,
279,
3643-3650.
|
 |
|
|
|
|
 |
D.Belorgey,
L.K.Sharp,
D.C.Crowther,
M.Onda,
J.Johansson,
and
D.A.Lomas
(2004).
Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB.
|
| |
Eur J Biochem,
271,
3360-3367.
|
 |
|
|
|
|
 |
S.Terzyan,
N.Wakeham,
P.Zhai,
K.Rodgers,
and
X.C.Zhang
(2004).
Characterization of Lys-698-to-Met substitution in human plasminogen catalytic domain.
|
| |
Proteins,
56,
277-284.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
D.Belorgey,
D.C.Crowther,
R.Mahadeva,
and
D.A.Lomas
(2002).
Mutant Neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro.
|
| |
J Biol Chem,
277,
17367-17373.
|
 |
|
|
|
|
 |
T.Oka,
T.Hakoshima,
M.Itakura,
S.Yamamori,
M.Takahashi,
Y.Hashimoto,
S.Shiosaka,
and
K.Kato
(2002).
Role of loop structures of neuropsin in the activity of serine protease and regulated secretion.
|
| |
J Biol Chem,
277,
14724-14730.
|
 |
|
|
|
|
 |
A.Pasternak,
A.White,
C.J.Jeffery,
N.Medina,
M.Cahoon,
D.Ringe,
and
L.Hedstrom
(2001).
The energetic cost of induced fit catalysis: Crystal structures of trypsinogen mutants with enhanced activity and inhibitor affinity.
|
| |
Protein Sci,
10,
1331-1342.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
R.Egelund,
T.E.Petersen,
and
P.A.Andreasen
(2001).
A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism.
|
| |
Eur J Biochem,
268,
673-685.
|
 |
|
|
|
|
 |
H.M.Zhou,
A.Nichols,
P.Meda,
and
J.D.Vassalli
(2000).
Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.
|
| |
EMBO J,
19,
4817-4826.
|
 |
|
|
|
|
 |
S.Wang,
G.L.Reed,
and
L.Hedstrom
(2000).
Zymogen activation in the streptokinase-plasminogen complex. Ile1 is required for the formation of a functional active site.
|
| |
Eur J Biochem,
267,
3994-4001.
|
 |
|
|
|
|
 |
Y.Tang,
J.Zhang,
L.Gui,
C.Wu,
R.Fan,
W.Chang,
and
D.Liang
(2000).
Crystallization and preliminary X-ray analysis of earthworm fibrinolytic enzyme component A from Eisenia fetida.
|
| |
Acta Crystallogr D Biol Crystallogr,
56,
1659-1661.
|
 |
|
|
|
|
 |
C.P.Sommerhoff,
W.Bode,
P.J.Pereira,
M.T.Stubbs,
J.Stürzebecher,
G.P.Piechottka,
G.Matschiner,
and
A.Bergner
(1999).
The structure of the human betaII-tryptase tetramer: fo(u)r better or worse.
|
| |
Proc Natl Acad Sci U S A,
96,
10984-10991.
|
 |
|
|
|
|
 |
H.Czapinska,
and
J.Otlewski
(1999).
Structural and energetic determinants of the S1-site specificity in serine proteases.
|
| |
Eur J Biochem,
260,
571-595.
|
 |
|
|
|
|
 |
H.Jing,
K.J.Macon,
D.Moore,
L.J.DeLucas,
J.E.Volanakis,
and
S.V.Narayana
(1999).
Structural basis of profactor D activation: from a highly flexible zymogen to a novel self-inhibited serine protease, complement factor D.
|
| |
EMBO J,
18,
804-814.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Shobe,
C.D.Dickinson,
and
W.Ruf
(1999).
Regulation of the catalytic function of coagulation factor VIIa by a conformational linkage of surface residue Glu 154 to the active site.
|
| |
Biochemistry,
38,
2745-2751.
|
 |
|
|
|
|
 |
K.P.Hopfner,
A.Lang,
A.Karcher,
K.Sichler,
E.Kopetzki,
H.Brandstetter,
R.Huber,
W.Bode,
and
R.A.Engh
(1999).
Coagulation factor IXa: the relaxed conformation of Tyr99 blocks substrate binding.
|
| |
Structure,
7,
989-996.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
S.Wang,
G.L.Reed,
and
L.Hedstrom
(1999).
Deletion of Ile1 changes the mechanism of streptokinase: evidence for the molecular sexuality hypothesis.
|
| |
Biochemistry,
38,
5232-5240.
|
 |
|
|
|
|
 |
A.Pasternak,
X.Liu,
T.Y.Lin,
and
L.Hedstrom
(1998).
Activating a zymogen without proteolytic processing: mutation of Lys15 and Asn194 activates trypsinogen.
|
| |
Biochemistry,
37,
16201-16210.
|
 |
|
|
|
|
 |
A.R.Khan,
and
M.N.James
(1998).
Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes.
|
| |
Protein Sci,
7,
815-836.
|
 |
|
|
|
|
 |
C.T.Esmon,
and
T.Mather
(1998).
Switching serine protease specificity.
|
| |
Nat Struct Biol,
5,
933-937.
|
 |
|
|
|
|
 |
M.A.Parry,
C.Fernandez-Catalan,
A.Bergner,
R.Huber,
K.P.Hopfner,
B.Schlott,
K.H.Gührs,
and
W.Bode
(1998).
The ternary microplasmin-staphylokinase-microplasmin complex is a proteinase-cofactor-substrate complex in action.
|
| |
Nat Struct Biol,
5,
917-923.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.T.Stubbs,
M.Renatus,
and
W.Bode
(1998).
An active zymogen: unravelling the mystery of tissue-type plasminogen activator.
|
| |
Biol Chem,
379,
95.
|
 |
|
|
|
|
 |
T.Selwood,
D.R.McCaslin,
and
N.M.Schechter
(1998).
Spontaneous inactivation of human tryptase involves conformational changes consistent with conversion of the active site to a zymogen-like structure.
|
| |
Biochemistry,
37,
13174-13183.
|
 |
|
|
|
|
 |
X.Wang,
X.Lin,
J.A.Loy,
J.Tang,
and
X.C.Zhang
(1998).
Crystal structure of the catalytic domain of human plasmin complexed with streptokinase.
|
| |
Science,
281,
1662-1665.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.Renatus,
M.T.Stubbs,
R.Huber,
P.Bringmann,
P.Donner,
W.D.Schleuning,
and
W.Bode
(1997).
Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage.
|
| |
Biochemistry,
36,
13483-13493.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
W.Bode,
and
M.Renatus
(1997).
Tissue-type plasminogen activator: variants and crystal/solution structures demarcate structural determinants of function.
|
| |
Curr Opin Struct Biol,
7,
865-872.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
');
}
}
 |